Drugs / iC9-CAR19 cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03016377 | Mar 2012 → Sep 2025 overdue | acute lymphoblastic leukemia, immunoproliferative disorder | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03594162 | — | acute lymphoblastic leukemia, immunoproliferative disorder | UNC Lineberger Comprehensive Cancer Center | No longer available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iC9-CAR19 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03016377 ↗ |
| Action | Deplete | “These CD19 chimeric (combination) receptor-activated T cells kill some of the tumor” NCT03016377 ↗ |
| Modality | Cell therapy | “autologous T lymphocyte chimeric antigen receptor cells” NCT03016377 ↗ |
| Target | CD19 | “CAR-T cells targeting the CD19 antigen” NCT03016377 ↗ |